US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% META $728.08 ▲+0.00% NVDA $233.95 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00% JNJ $256.03 ▲+0.00% SPCX $158.96 ▲+0.00%
FinancialContent

Articles published by Acasti Pharma, Inc.

News headline image
Acasti Pharma Reports Third Quarter 2023 Operational Results
From Acasti Pharma, Inc.
Via GlobeNewswire
Tickers ACST TSX-V:ACST
News headline image
Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule
From Acasti Pharma, Inc.
Via GlobeNewswire
Tickers ACST TSX-V:ACST
News headline image
Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31
From Acasti Pharma, Inc.
Via GlobeNewswire
Tickers ACST TSX-V:ACST
News headline image
Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18
From Acasti Pharma, Inc.
Via GlobeNewswire
Tickers ACST TSX-V:ACST
News headline image
Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures
From Acasti Pharma, Inc.
Via GlobeNewswire
Tickers ACST TSX-V:ACST
News headline image
Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
From Acasti Pharma, Inc.
Via GlobeNewswire
Tickers ACST TSX-V:ACST
News headline image
Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)
From Acasti Pharma, Inc.
Via GlobeNewswire
Tickers ACST TSX-V:ACST
News headline image
Acasti Pharma Reports Second Quarter 2023 Operational Results
From Acasti Pharma, Inc.
Via GlobeNewswire
Tickers ACST TSX-V:ACST
News headline image
Acasti Pharma to Present at Q4 Investor Summit
From Acasti Pharma, Inc.
Via GlobeNewswire
Tickers ACST TSX-V:ACST
News headline image
Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022
From Acasti Pharma, Inc.
Via GlobeNewswire
Tickers ACST TSX-V:ACST
News headline image
Acasti Announces Court Dismissal of Stockholder Litigation
From Acasti Pharma, Inc.
Via GlobeNewswire
Tickers ACST TSX-V:ACST
News headline image
Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders
From Acasti Pharma, Inc.
Via GlobeNewswire
Tickers ACST TSX-V:ACST
News headline image
Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia
From Acasti Pharma, Inc.
Via GlobeNewswire
Tickers ACST TSX-V:ACST